SynKIR-310 for Relapsed/Refractory B-NHL
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Diffuse Large B Cell Lymphoma
Related studies linked through entity extraction aliases.
DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL
- Status
- RECRUITING
- Phase
- PHASE2
Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
- Status
- RECRUITING
- Phase
- PHASE2
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment
- Status
- RECRUITING
- Phase
- N/A
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Maintenance Hormonal Therapy and DLBCL
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2/PHASE3
Is Trogocytosis a Predictive Marker of CAR-T Cell Response in Diffuse Large B-cell Lymphoma?
- Status
- RECRUITING
- Phase
- NA
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
- Status
- WITHDRAWN
- Phase
- PHASE1
Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients
- Status
- RECRUITING
- Phase
- PHASE2
Characterization and Clinical Impact of the Gut Microbiota in Lymphoma
- Status
- RECRUITING
- Phase
- N/A
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2